LEXINGTON, Mass.—Beth Marsh joined Shire’s ophthalmic team as commercial strategy lead for SHP640, the development program for a drug being investigated to treat infectious conjunctivitis (adenoviral and bacterial).

Marsh comes to Shire with more than 20 years’ experience. Most recently, she was working at her own consulting firm to assist development-stage ophthalmic pharmaceutical and medical device companies prepare for commercial success, acquisition, or investment. She’s held leadership roles across key functions and was a key team member working on the commercial launches for the ophthalmic business units at Johnson & Johnson, Novartis, Santen and Akorn.

As commercial lead strategy lead, she will be responsible for building the commercial launch plan for SHP640 as the product advances through the development cycle at Shire.